Medivir
2,61
SEK
0 %
MVIR
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
2 investorer følger denne virksomhed
0%
-9,38%
-10,31%
-18,18%
-8,42%
-5,11%
-69,07%
-78,73%
-95,55%
Medivir is a pharmaceutical company. The company develops drugs and treatments with a focus on cancers and other serious diseases. The company invests in indication areas where available treatment methods are limited or completely lacking research. Collaborations with other partners are part of the business model, and drug development, as well as commercialization, are conducted either in-house or in partnership with other pharmaceutical companies. The head office is located in Huddinge.
Læs mereMarkedsværdi
299,15 mio. SEK
Aktieomsætning
1,22 mio. SEK
Omsætning
7,6 mio.
EBIT %
-1.202,63 %
P/E
-
Udbytteafkast, %
-
Finanskalender
18.2
2025
Årsrapport '24
29.4
2025
Delårsrapport Q1'25
7.5
2025
Generalforsamling '24
ViserAlle indholdstyper
BioStock: Medivir's phase Ib/IIa study successfully concluded
Medivir announces finalisation of the phase 1b/2a study with fostrox + Lenvima in advanced liver cancer, remaining patients transferred to compassionate use
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools